Life sciences company secures exclusive distribution deal
York-based life sciences business OptiBiotix says its wholly-owned subsidiary, ProBiotix Health, has signed an exclusive distribution agreement with Ayalla Marketing.
This is for the distribution of its cholesterol reducing probiotic, LPLDL®, as an ingredient and as four finished products (CholBiome, CholBiomeX3, CholBiomeBP and CholBiomeVH) within the CholBiome® portfolio for Brazil.
The agreement is for an initial period of 12 months and has modest minimum order quantities for each product, providing the company security of income and revenue growth.
Ayalla was founded in 1973 to provide Active Pharmaceutical Ingredients for the pharmaceutical industry.
It has a product portfolio developed to meet the need of veterinary, food, cosmetics and fragrance industries.
Ayalla has developed a network of suppliers in Europe, the US and Asia, which enables it to offer high quality products and services and is a well-known and established distributor of pharmaceutical and nutraceutical products in Brazil.
Mikkel Hvid-Hansen, commercial director of ProBiotix Health, said: “We are pleased to announce the signing of this distribution agreement with Ayalla.
“Ayalla is an established distributor with a national reputation and wide network of contacts.
“We chose Ayalla because of its reputation and expertise in commercialising pharmaceutical and non-drug products with strong science and clinical studies in the Brazilian market.”